Oxcarbazepine add-on in the treatment of refractory bipolar disorder

Bipolar Disorders, Supplement

Volumn 7, Issue 5, 2005, Pages 37-42

  Pratoomsri, Wetid ^a   Yatham, Lakshmi N ^a   Sohn, Chang Ho ^a   Solomons, Kevin ^a   Lam, Raymond W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Add on treatment; Bipolar II; Depression; Oxcarbazepine; Refractory bipolar disorder

Indexed keywords

AMFEBUTAMONE; BENZATROPINE MESILATE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LEVOTHYROXINE; LIOTHYRONINE SODIUM; LITHIUM; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZOPICLONE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; HYPOMANIA; HYPONATREMIA; LEG DISEASE; MALE; MEDICAL RECORD; MENTAL PATIENT; MOOD DISORDER; NAUSEA; NOCTURIA; POLYURIA; PRESCRIPTION; PRIORITY JOURNAL; RASH; SCHIZOAFFECTIVE PSYCHOSIS; SCORING SYSTEM; SKIN DISEASE; SLEEP DISORDER; SLURRED SPEECH; SOMNOLENCE; TINNITUS; TREMOR; UNIVERSITY HOSPITAL; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN;

ADULT; AGED; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES;

EID: 29544449111     PISSN: 13992406     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2005.00253.x     Document Type: Article

References (27)

1. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
2. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
3. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407.
4. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl.) 2000; 150: 15-23.
5. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12: 42S-52S.
6. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 395-405.
7. Keck PE Jr, McElroy SL. Divalproex in the treatment of bipolar disorder. Psychopharmacol Bull 2003; 37(Suppl. 2):67-73.
8. Keck PE Jr, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry 2002; 63(Suppl. 10):13-17.
9. Hirschfeld RM, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004; 7: 507-522.
10. Beydoun A. Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disorders. Epilepsy Behav 2002; 3: S18-S22.
11. Gram L. Clinical experience with oxcarbazepine. Epilepsia 1994; 35(Suppl. 3):S21-S22.
12. Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217-1220.
13. Larkin JG, McKee PJ, Forrest G et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65-71.
14. Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano GB. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004; 79: 273-277.
15. Emrich HM. DMvZD: Action of Sodium-Valproate and of Oxcarbazepine in Patients with affective Disorders in Anticonvulsants in affective Disorders Edited by Emrich HM OTMA. Amsterdam: Excerpta Medica, 2005.
16. Emrich HM, Altmann H, Dose M, Von ZD. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav 1983; 19: 369-372.
17. Emrich HM, Dose M, Von ZD. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-250.
18. Hummel B, Walden J, Stampfer R et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002; 4: 412-417.
19. Ghaemi SN, Ko JY, Katzow JJ. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disord 2002; 4: 70-74.
20. Velikonja M HK. Effect of Oxcarbazepine (GP 47.680) on affective and Schizoaffective Symptoms: a Preliminary Report in Anticonvulsants in affective Disorders Edited by Emrich HM OTMA. Amsterdam: Excerpta Medica, 1984.
21. Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003; 64: 943-945.
22. Centorrino F, Albert MJ, Berry JM et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003; 5: 370-374.
23. Raja M, Azzoni A. Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders. Int J Neuropsychopharmacol 2003; 6: 409-414.
24. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 2001; 34: 242-250.
25. Pendlebury SC, Moses DK, Eadie MJ. Hyponatraemia during oxcarbazepine therapy. Hum Toxicol 1989; 8: 337-344.
26. Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988; 2: 269-271.
27. Kumar S, Berl T. Sodium. Lancet 1998; 352: 220-228.